Fibrocell Science — IPO Roadshow (November 2017)
21 slides from Fibrocell Science's IPO roadshow presentation, Nov 17, 2017
Slide 1: Forward-Looking Statements and Disclaimer
Forward-Looking Statements and Disclaimer This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking stateme
Slide 2: Fibrocell at a Glance
3 Fibrocell at a Glance Personalized medical breakthroughs for diseases of the skin and connective tissue Three patients dosed and interim data reported First adult patient enrolled in Phase 2 Additional dosing of adult patients expected in 4Q17 Pediatric enrollment expected in 1Q18 Orphan Drug Desi
Slide 3: Our Autologous Fibroblast Gene Therapy Platform
4 Our Autologous Fibroblast Gene Therapy Platform Delivery Vehicle Vector Ex vivo Modification FCX-007 autologous dermal fibroblasts in culture Autologous fibroblasts harvested from patients Readily sourced, as fibroblasts are the most common cell type in skin and connective tissue Reduced rejection
Slide 4: Personalized Biologics Approach
Personalized Biologics Approach 5
Slide 5: Development Pipeline
Development Pipeline 6 Program Condition Target Research Pre-Clinical Development Human Clinical Trials FCX-007 Recessive Dystrophic Epidermolysis Bullosa (RDEB) Type VII Collagen FCX-013 Moderate to Severe Localized Scleroderma MMP-1 Research Arthritis and Related Conditions TBD
Slide 6: FCX-007 Providing Hope for RDEB Patients
FCX-007 Providing Hope for RDEB Patients 7 RDEB patients do not produce type VII collagen (COL7) due to mutation in COL7A1 gene Main component of anchoring fibrils that connect skin layers FCX-007 is an autologous human dermal fibroblast transduced with a lentiviral (LV) vector encoded for COL7A1 Lo
Slide 7: About RDEB
About RDEB 8 Disease Current Treatments Epidemiology Cause: A mutation in the COL7A1 gene that encodes for COL7 Devastating, progressive, painful blistering disease that often leads to death Diagnosed at infancy High mortality rate – 76% of RDEB patients do not live past their 30’s1 Current treatmen
Slide 8: Functional COL7 Expression Confirmation
Functional COL7 Expression Confirmation 9 Culture supernatant evaluated for in vitro COL7 expression ELISA assay indicates virus dose-dependent protein expression Trimeric form of COL7 produced by RDEB patient fibroblasts transduced with LV-COL7 Must be trimeric to be functional Reference: Bruckner-
Slide 9: Treating Underlying Pathology of RDEB
RDEB Patient’s Non-Transduced Fibroblasts RDEB patients lack COL7A1 gene that plays critical role forming anchoring fibrils & providing integral stability to skin In vitro studies show production of functional trimeric structure COL7 which RDEB patients lack capability to produce In vivo studies sho
Slide 10: FCX-007 Phase 1/2 Clinical Trial Design
FCX-007 Phase 1/2 Clinical Trial Design 11 Title A Phase 1/2 Trial of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa (RDEB) NCT02810951 Primary Objective To evaluate the safety of a single intradermal injection session of FCX-007 Sec
Slide 11: FCX-007 Interim Data Readout
FCX-007 Interim Data Readout Interim readout of data for three NC1+ adult Phase 1 patients, 12 weeks post-administration Single injection session of FCX-007 to target wounds or preliminary safety assessment Five wounds treated over three patients; wounds ranged from 4.4cm2 to 13.1cm2 FCX-007 was wel
Slide 12: FCX-007 Interim Readout: Wound Healing
FCX-007 Interim Readout: Wound Healing Digital images captured and tracings performed Skin tattoos and transparent overlays used as landmarks Wounds monitored in the study prior to dosing were open at each monitoring visit up to 8 months Compared to the baseline measurement collected at Day 0 pre-ad
Slide 13: FCX-007 Interim Readout: Pharmacology
FCX-007 Interim Readout: Pharmacology 14 Texas Red – C7/fNC1 + DAPI + FITC – laminin 332 Texas Red – C7/fNC1 Variable pharmacology signals detected throughout the data set in each patient for one or more assays through 12 weeks post-administration (qPCR, electron microscopy, immunofluorescence) Anch
Slide 14: Manufacturing Experience and Solutions
Fibrocell’s existing cGMP cell therapy manufacturing facility in Exton, PA has been designated as the production site for FCX-007 after incorporation into the IND ~13,000 square foot facility includes: Cleanroom for cell culture manufacturing On-site quality control testing laboratories Cryogenic st
Slide 15: FCX-013 Development Progressing
FCX-013 Development Progressing 16 Product profile Autologous fibroblasts genetically modified using lentivirus and encoded for matrix metalloproteinase 1 (MMP-1), a protein responsible for breaking down collagen Target protein known to breakdown collagens Incorporates Intrexon’s RheoSwitch Therapeu
Slide 16: Localized Scleroderma Disease Epidemiology
Localized Scleroderma 17 Disease Epidemiology Excess production of collagen characterized by skin fibrosis and scars Focus on moderate to severe subtypes, including linear Thickening may extend to underlying tissue and muscle in children which may impair growth in affected limbs or forehead Lesions
Slide 17: FCX-013 Proof-of-Concept Study
FCX-013 Proof-of-Concept Study 18 Study Design Bleomycin treated SCID mouse model N=30 mice over test and control groups Assessed histologically for reduction of dermal thickness and sub-dermal muscle in the presence of FCX-013 and oral ligand Result Bleomycin treatment resulted in skin fibrosis, me
Slide 18: Research Program for Arthritis
Research Program for Arthritis 19 Deliver therapeutic protein locally to the joint providing sustained efficacy while avoiding key side effects typically associated with systemic therapy Combines Fibrocell’s autologous fibroblast technology with Intrexon’s cellular engineering to develop localized g
Slide 19: Milestones and Financials
Program Milestone Timing FCX-007 FDA grants Fast Track Designation January 2017 FCX-007 Phase 1/2 trial first adult patient dosed February 2017 FCX-007 DSMB recommendation (after 1 patient) April 2017 FCX-013 FDA grants Rare Pediatric Disease Designation June 2017 FCX-007 Phase 1/2 trial interim upd
Slide 20: References
References 1 Fine, J. et. al. (ed.). Epidermolysis Bullosa: Clinical, Epidemiologic, and Laboratory Advances and the Findings of the National Epidermolysis Bullosa Registry. The John Hopkins University Press, Baltimore, MD, 1999. 2 The Dystrophic Epidermolysis Research Association of America (DebRA)
Slide 21: References
References 1Fine, J. et. al. (ed.). Epidermolysis Bullosa: Clinical, Epidemiologic, and Laboratory Advances and the Findings of the National Epidermolysis Bullosa Registry. The John Hopkins University Press, Baltimore, MD, 1999. 2 The Dystrophic Epidermolysis Research Association of America (DebRA).